对帕金森病患者运动和非运动症状的血清神经递质分析
Yichun Fan1,2, Wenping Yang3, Weilan Wu1,2
1Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Frontiers in aging neuroscience
|December 10, 2024
概括
帕金森病 (PD) 涉及神经递质代谢的改变,特别是在托通路中,影响运动和非运动功能. 这项研究确定了PD的新生物标志物和潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 临床神经学 临床神经学
背景情况:
- 帕金森病 (PD) 呈现出运动和非运动症状,包括抑郁症.
- 在PD中非运动性症状的潜在机制尚未完全理解.
- 神经递质失衡与PD的心理健康方面有关.
研究的目的:
- 为了研究帕金森病患者神经递质代谢的改变.
- 探索神经递质水平与PD中的临床症状 (运动和非运动) 之间的关系.
- 确定PD的潜在生物标志物和治疗点.
主要方法:
- 来自PD患者和对照组的血清样本使用超高性能液态染色学-双重质谱法 (UPLC-MS/MS) 分析了21种神经递质.
- 临床严重程度使用标准化尺度进行评估:UPDRS,NMSS,MMSE,HAMA和HAMD.
- 分析了神经递质转化率和神经递质水平与临床分数之间的相关性.
主要成果:
- 在托代谢途径中观察到显著的变化,托 (Trp),金氨酸 (KYN),金氨酸 (KA),尼古丁胺胺 (NAM) 和5-甲氧化三胺 (MeOTA) 的水平降低.
- 激发性/抑制性氨基酸,包括谷氨酸 (Glu),4-氨基黄油酸 (GABA) 和酸 (Asp) 的水平也降低了.
- 特定的神经递质的比率和水平 (例如,桑氨酸,5-西胺,GABA) 与运动和非运动症状的严重程度相关.
结论:
- 改变神经递质代谢,特别是在托通路内,与帕金森病有关.
- 特定的神经递质的变化与PD患者的运动和非运动症状严重程度相关.
- 这些发现表明PD管理的新生物标志物和治疗点.
相关概念视频
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479


